Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779 is registered in ClinicalTrials.gov with Rivus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05979779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Lead sponsor
Rivus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 5, 2023
Completion date
June 30, 2025
Enrollment
219 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

fatty liver, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis